Thyroid Eye Disease
Co-Pay Relief Program Fund Notices
Would you like to be notified when any new funds open, or when any of our current funds re-open? If so, please sign up using the “Get Notified” link below. As a member of our subscriber community you will receive important news about all of our disease funds, so join today!
Approved and Donation Ready
This fund has been developed in response to patients who have contacted PAF for help with their medication expenses and could not find help. While this fund has been fully designed and we are ready to provide needed support to these patient communities, this fund is not yet able to accept applications for assistance as we are still working to secure charitable donations that will allow us to open it.
If you, or someone you know, would like to contribute to this fund, please visit our Donors page for more information on how to provide critical support for patients in need.
Fund Type
- Co-pay, Co-insurance & Deductibles
- Office visits and administration charges related to treatment
- Medical Insurance premiums
$4,500
- Household Income Requirements 400% or less of Federal Poverty Guideline (FPG) (adjusted for Cost of Living Index (COLI) and number in household)
- Insurance Requirements All Insurance Types
- Must reside and receive treatment in the United States.
About Thyroid Eye Disease
Thyroid Eye Disease (TED) is characterized by progressive inflammation and damage to tissues around the eyes. Progressive inflammation, swelling, and tissue changes occur. Associated symptoms include pain, gritty feeling in the eyes, swelling or abnormal poisoning of the eyelids, watery eyes, bulging eyes, or double vision. TED is an autoimmune disorder in which the body’s immune system mistakenly attacks healthy tissue.
TED most commonly occurs as part of Graves’ Disease (autoimmune disease of the thyroid) however, it can also occur in people with an underactive thyroid such as Hashimoto thyroiditis. Approximately 90% of the cases of TED occur in the setting of Graves’ Disease. While TED often occurs in people living with hyperthyroidism or Graves’ disease, it is a distinct disease and treating hyperthyroidism may not resolve the eye symptoms and signs.
While the exact prevalence is unknown, it is estimated that 16 per 100,00 women and 2.9 per 100,000 men in the general population are affected.
Other potential terms for this disease include: Graves’ orbitopathy, Graves’ ophthalmopathy, Graves’ eye disease, thyroid-associated orbitopathy, or thyroid-associated ophthalmopathy.
- CancerCare866-55-COPAY
- Good Days877-968-7233
- Healthwell Foundation800-675-8416
- National Organization for Rare Disorders800-999-6673
- Needy Meds800-503-6897
- Patient Access Network Foundation866-316-7263
- Patient Services Inc.800-366-7741
- The Assistance Fund855-845-3663
